Aurisco PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 5/6
Aurisco PharmaceuticalLtd has a total shareholder equity of CN¥2.3B and total debt of CN¥847.3M, which brings its debt-to-equity ratio to 37.4%. Its total assets and total liabilities are CN¥3.7B and CN¥1.4B respectively. Aurisco PharmaceuticalLtd's EBIT is CN¥365.7M making its interest coverage ratio -18.1. It has cash and short-term investments of CN¥1.1B.
Key information
37.4%
Debt to equity ratio
CN¥847.28m
Debt
| Interest coverage ratio | -18.1x |
| Cash | CN¥1.13b |
| Equity | CN¥2.27b |
| Total liabilities | CN¥1.42b |
| Total assets | CN¥3.69b |
Recent financial health updates
Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?
Sep 19
Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet
Jun 07Recent updates
Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?
Sep 19Is Now The Time To Put Aurisco PharmaceuticalLtd (SHSE:605116) On Your Watchlist?
Aug 14Investors Interested In Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Earnings
Jun 28Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet
Jun 07Investors Shouldn't Be Too Comfortable With Aurisco PharmaceuticalLtd's (SHSE:605116) Earnings
May 12Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today
Apr 22Financial Position Analysis
Short Term Liabilities: 605116's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥537.8M).
Long Term Liabilities: 605116's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥884.9M).
Debt to Equity History and Analysis
Debt Level: 605116 has more cash than its total debt.
Reducing Debt: 605116's debt to equity ratio has increased from 0% to 37.4% over the past 5 years.
Debt Coverage: 605116's debt is well covered by operating cash flow (47%).
Interest Coverage: 605116 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 01:40 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aurisco Pharmaceutical Co.,Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Shitong Han | Citic Securities Co., Ltd. |
| Wenxin Yu | Haitong International Research Limited |